The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 11 of 19137
Back to Result List

Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride

Please always quote using this URN: urn:nbn:de:bvb:20-opus-279893
  • Purpose Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated. Methods Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany andPurpose Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated. Methods Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures. Results In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs. Conclusions This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml).show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Stefanie Fekete, K. Egberts, T. Preissler, C. Wewetzer, C. Mehler-Wex, M. Romanos, M. Gerlach
URN:urn:nbn:de:bvb:20-opus-279893
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie
Language:English
Parent Title (English):European Journal of Clinical Pharmacology
Year of Completion:2021
Volume:77
Issue:2
Pagenumber:163-170
Source:European Journal of Clinical Pharmacology (2021) 77:163–170. https://doi.org/10.1007/s00228-020-03000-0
DOI:https://doi.org/10.1007/s00228-020-03000-0
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/32986159
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:Tourette syndrome; paediatrics; pharmacokinetics; serum concentration; therapeutic drug monitoring
Release Date:2024/04/18
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International